Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript
Ocugen(US:OCGN) Seeking Alpha·2026-03-24 21:54PresentationOperator Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related Macular Degeneration. Please note that this call is being recorded. [Operator Instructions] I would now like to turn the call to Tiffany Hamilton, Ocugen's Head of Corporate Communications. Please go ahead. ...